host lymphoid cells in vitro was applied to study specific cell immunity in mammary tumor virus-free C3HeB/Fe mice. These mice bore neoplasms produced by inoculation of a cell line developed from a syngeneic spontaneous mammary tumor. Peritoneal washings were used as the source of lymphoid cells so that the mice could be checked periodically to Follow the evolution of their specific immunological status during tumor growth and after surgical removal of the tumor, followed or not by other treatment. As previously demonstrated in other host-tumor systems, peritoneal cells taken from animals at the beginning of tumor growth had a moderate, but significant, specific immunological activity which disappeared entirely when the tumors reached 7 mm or more in diameter. AFter surgical removal of the tumors, this activity reappeared but only after a delay of nearly 20 days. This delay could be significantly shortened if the animals were inoculated subcutaneously, 4 days after surgery, with their own tumor cells that had been trypsinbed, irradiated, and frozen.-j Nat Cancer lnst 46: 981-987, 1971.
SUMMARY-The test of colony growth inhibition of target tumor cells by
host lymphoid cells in vitro was applied to study specific cell immunity in mammary tumor virus-free C3HeB/Fe mice. These mice bore neoplasms produced by inoculation of a cell line developed from a syngeneic spontaneous mammary tumor. Peritoneal washings were used as the source of lymphoid cells so that the mice could be checked periodically to Follow the evolution of their specific immunological status during tumor growth and after surgical removal of the tumor, followed or not by other treatment. As previously demonstrated in other host-tumor systems, peritoneal cells taken from animals at the beginning of tumor growth had a moderate, but significant, specific immunological activity which disappeared entirely when the tumors reached 7 mm or more in diameter. AFter surgical removal of the tumors, this activity reappeared but only after a delay of nearly 20 days. This delay could be significantly shortened if the animals were inoculated subcutaneously, 4 days after surgery, with their own tumor cells that had been trypsinbed, irradiated, and frozen.-j Nat Cancer lnst 46: 981-987, 1971.
RECENTLY two of us (1, 2) reported on the evolution of the specific cell-immunity status of BALB/c mice bearing tumors produced by inoculation of a syngeneic neoplastic cell line having a strong virus-induced antigenic marker. Since peritoneal washings were used as the source of immunologically competent cells, specific cell immunity could be tested repeatedly by the in vitro colonyinhibition technique on the same group of mice and even on the same individual animals (2), in order to follow and quantitate the cell immunity in time as a function of the tumor growth and its treatmentby surgery in particular.
as the activity of lymphoid cells collected from the peritoneal cavity against target tumor cells) had a characteristic evolution: The cell immune activity, marked at the beginning of tumor growth, disappeared when the tumors reached 10 mm or more in diameter; however, it reappeared after the tumors This study revealed that cell immunity (expressed 982 LE FRANgOIS, YOUN, BELEHRADEK, AND BARSKI were surgically removed, but only after a delay of 7-21 days. Reinoculation of the animal, a few days after surgery, with its own irradiated tumor cells significantly shortened this delay.
We report here on a similar study with another neoplastic line, developed from a spontaneous mammary tumor of a C3H mouse. In accord with data reported by several investigators (3-5), we could demonstrate the immune reaction of the animal against these syngeneic tumors. However, we gained more insight using quantitative in vitro tests, which revealed a particular evolution of cell immunity in mice bearing these tumors: primary activity at the beginning of neoplastic growth, an "eclipse" period when the tumor increased in size, and recovery of the specific cell immunity after some delay following tumor excision. In addition, we report· on experiments in which surgically treated animals were immunologically stimulated.
MATERIALS AND METHODS
Mice.-Inbred adult females of the mammary tumor virus (MTV)-free C3HeB/Fe strain were used. They were obtained from the Animal Selection Center, Orleans, France, and were maintained by continuotis brother X sister mating.
Cell cultures.-The TM I in vitro cell line was developed in our laboratory [rom a spontaneous mammary tumor of a C3H mouse. After serial transfers in vivo and 2 successive in vitro clonings, it was routinely cultivated in a I : I mixture of Eagle's minimal essential and NCTC 109 chemically defined media supplemented with 10% decomplemen ted calf serum. Budding B-type particles, as well as intracytoplasmic A-type particles, as described by Bernhard (6) and others, were observed by electron microscopy in TMI cells ( fig. 1 ). When inoculated subcutaneously in doses of 5 X 10 4 cells or more into adult C3HeB/Fe mice, these cells produced rapidly growing and killing tumors.
Colony growth inhibition (CGI) test.-To check in vitro the specific cell immunity against the TMI target cells, we used the previously described method (1) modified from Hellstrom's colony-inhibition technique (7) . In brief, Falcon plastic petri dishes (60 X 15 mm) were seeded with 500 monodispersed TM I cells per dish. After 24 hours' incubation at 37°C in 5% CO 2 atmosphere, 7 X 10 6 peritoneal cells (PC) were added, contammg a nearly equal proportion of lymphocytes and macrophages (45-50%). The cells were obtained by rinsing the peritoneal cavity of unanesthetized mice with culture medium containing 5 V/ml of heparin. One to six million PC were harvested per mouse. The rinsing was performed by injection and aspiration of 5 ml medium through a specially designed multi perforated needle (1). The same parallel groups of mice were sequentially checked for their PC activity. Twenty-four hours after introduction of the PC, the culture medium was renewed and the petri dishes were incubated for another 10-15 days. The cell colonies developing were then stained and counted. The usual cloning efficiency of the TM 1 cell line was 20-30%; it increased significantlyt03G-37%when PC from normal C3HeB/-Fe mice were added to the cultures.
RESULTS
The antigenicity of the TM I cell line for the C3HeB/Fe mice could be demonstrated in vivo by the rejection of these cells when inoculated into mice preimmunized by repeated intraperitoneal injections of the TMI cells irradiated. Furthermore, immunity developing in mice preinoculated with irradiated cells could be detected by the CGI test in vitro by use of PC cells from the immunized animals. The inhibition approximated, under these conditions, 64-100% (table I). The specificity of the sensitization of these PC was demonstrated by their inability to suppress colony growth of other, nonrelated homologous tumor cells like the BALB/c T5 cells (unpublished data).
These observations were a starting point for further investigations on the quantitative analysis of the specific cell immunity as dependent on tumor growth and treatment.
In 8 independent experiments extending over a period of 14 months and including 322 mice, 10 6 TMI cells were routinely inoculated subcutaneously into C3HeB/Fe mice. The tumors, developing in nearly 100% of the inoculated mice, were followed and their diameters measured and recorded. When reaching 10 mm in diameter, approximating I g of weight, the tumors were removed surgically in some groups of mice. With few exceptions, tumor growth did not recur. Periodically, PC from determined groups of mice were sampled, pooled, and used in CGI tests. Text- figure 1 shows the results of 3 experiments in which the specific cell immunity was evaluated in groups of mice, as dependent on time after inoculations and tumor size. Between the 7th and 9th day after inoculation of TMI cells, when the mean diameter of the tumors was 2-3 mm, the PC taken from these mice showed a moderate, 21% in average, but significant inhibition (P = 0.05) of TMI colony growth. In some more recent experiments, the inhibition with PC from "young" tumors reached a level even as high as 68%. However, in all cases, 16 days after inoculation or later, when the tumors grew to 7 mm or more in diameter, the PC entirely lost their inhibitory capacity in the CGI tests. Even a reverse, enhancing effect elicited by PC from animals bearing huge tumors on TMI cell growth in vitro was frequently observed.
Surgical removal of the animals' tumors which had reached, 35-40 days after inoculation, an a verage diameter of 12-15 mm had a definitely beneficial, though not immediate, effect on the specific cell immunity. As text-figure 2 indicates, 7 days after surgery the mice were still in an immunological "eclipse" period, with their PC inactive against TMI cell growth in vitro; but this activity reappeared spontaneously and reached high levels beginning on the 23d day after surgery and was maintained on a rather high level for at least another 27 days.
In other experiments, we tried to shorten the immunological "eclipse" stage extending over the postsurgery period by inoculating the surgically treated animals with their own irradiated tumor cells. The excised tumors were trypsinized; the cell suspension that was obtained was irradiated at 10,000 R and stored at -70°C. The animals were inoculated subcutaneously on the 4th day after surgery with 10 7 cells. Controls were: 1) intact mice receiving the same injection of irradiated tumor cells, 2) surgically treated, uninoculated mice, and 3) surgically treated mice inoculated in the same way as the first group but with 10 7 homologous (BALB/c mice) normal spleen cells. of tumol~{mmJ TEXT-FIGURE 2.-TMI CGI by PC from mice before and after surgical removal of TMI tumors. Each figure represents the percent of CGI obtained from a "vertical" experiment, in which PC were taken from 10 experimental mice that were checked repeatedly at the 7th, 23d, 37th, 41st, and 50th day after surgery, as compared with a group of 10 normal control mice checked at the same times. • TEXT-FIGURE 3.-CGI by PC from mice before and after surgical removal ofTMI tumors, followed or not followed by inoculation of irradiated tumor cells. Eighty mice were inoculated with 10 6 TMI cells on day 0, and their tumors removed surgically on the 27th day. The mice were divided into 3 subgroups (2, 3, and 4) treated differently as indicated. Controls were 20 intact mice inoculated with the same dose of irradiated tumor cells (group I). Each CGI figure represents the average value of CGI obtained with PC taken from each experimental group of nearly 25 mice. The difference between CGI of group I and group 3 (24 and 59%. respectively) was highly significant (P<O.OOI).
As shown in text-figure 3, PC from surgically treated mice, which received at the 4th day after surgery one injection of their own tumor cells, appeared to be rapidly and strongly activatedin fact, much more than PC from intact control mice given injections in the same way. The specificity of the "booster" effect was confirmed by the nonresponsiveness of the last control group of surgically treated mice receiving an inoculum of homologous spleen cells. A more systematic and quantitative study of the evolution of cell immunity in mice bearing tumors produced by inoculation of a syngeneic mammary tumor cell line was undertaken with the aid of the test in vitro in which we used peritoneal washings as a source of immunologically competent and specifically sensitized cells. The present experiments, in addition to our previous data and findings of several other authors, show that the PC, containing nearly the same proportion of lymphocytes and macrophages, appeared as a reliable source of immunocompetent cells for the demonstration of cell immunity in vitro (10) (11) (12) and in vivo (13) . The role of lymphocytes and macrophages in inhibiting target cell colony growth in vitro is, so far, unclear and is being studied in our The essential conclusion to be drawn from the present experiments is that, like in the previous study on the BALB/c-T5 antigenic tumor (1, 2) the cell immunity, expressed as specific in vitro activity of PC against target tumor cells, evolves with time and follows a well-defined pattern depending on the presence, growth, or elimination of the tumor mass.
Thus, mice with TM 1 tumors at the beginning of their growth supplied PC that could suppress significantly the growth of target tumor cells in vitro. However, this activity was totally "eclipsed" when PC were taken from mice with tumors 7 mm or more in diameter, which exceeded 1 g or one-twentieth the average body weight. From preliminary data obtained from experiments in progress in our laboratory, we can assume that the cell immunity "eclipse," observed in animals bearing advanced tumors, was essentially specific for the given tumor.
No satisfactory explanation is, so far, available for the paradoxical effect of enhancement of TMI colony growth in vitro by PC from animals bearing huge TMI tumors, a phenomenon observed also in our previous experiments with the T5 tumors (1). As judged from the present state of our experimentation, possibly the inefficiency and even the enhancing' effect of the PC during the "eclipse" period are due to the production of blocking an tibodies by these cells in vitro (J 4) .
The tumor-bearing mice entering the "eclipse" period, as indicated by a drop of CGI capacity of their PC, could be released from this state and recover this capacity if their tumors were removed surgically. However, this recovery occurred only after a considerable delay following the surgery. Once recovered, the specific immunological activity of PC was maintained at a high level for the duration of the testing period (4 weeks) and probably for longer.
Depletion of cell-mediated immunological activity in tumor-bearing animals and in patients was observed by several authors (15) (16) (17) . However, precise data are scarce on the evolution of the immunological status as dependent on the increase or elimination of the tumor mass. corresponding tumor cells, showed no depressive action on their growth in vivo; however, the lymphoid cells showed full activity when taken from rats 3 weeks after surgical removal of the tumor.
Using the in vitro colony-inhibition test, Heppner and Pierce (5) studied cell immunity in MTV-free BALB/c mice bearing syngeneic, transplanted mammary tumors. They found a rather uniform suppressive action of lymphoid cells on the colony growth of the target tumor cells. However, in most of their experiments, they tested the tumor cells 7-28 days after explantation in vitro and took the lymphoid cells from the surgically treated animals 6-26 days after the tumors were excised. In other words, the immunological status of the animals was checked mostly 1-4 weeks after the tumors were removed, which corresponds grossly to the period of immunological reactivation appearing with some delay following surgery that we observed in our experiments.
Also using the in vitro coiony-inhibition test, Hellstrom and his group studied cell immunity in animals bearing different types of tumors. They found, like Heppner and Pierce, that host lymphoid cells were specifically active rather uniformly against their own or syngeneic target tumor cells (18) (19) (20) . However, unlike our experiments, these authors used lymph node cells from animals that had been killed and did not systematically check the evolution of cell immunity in time as a function of tumor growth or removal.
As in our previous experiments on BALB/c mice bearing T5 tumors (1), and also according to more recent data obtained in experiments with a 3-methylcholanthrene-induced sarcoma in C57BL mice (21) , inoculating the surgically treated micebooster-like effect that could be obtained when the bulk of the tumor cells was eliminated.
Several attempts were made recently to treat patients with their own or homologous, irradiated neoplastic cells on the assumption that these cells are antigenic. This treatment was usually done after elimination, as complete as possible, of the tumor mass by conventional therapeutic methods. Although some results have been encouraging (22, 23) their clear-cut and statistically valid evaluation is still difficult.
Further investigations, with different syngeneic animal host-tumor systems, involving precise determinations of specific immunological activity of the host lymphoid cells, are necessary before a definite conclusion can be reached on the value of postsurgery treatment with the host's own autochthonous, irradiated tumor cells. On the other hand, though the specific immunological activity of the PC is certainly a pertinent indication, the exact relationship between this activity and the capacity of the host to destroy its tumor cells is still to be determined.
